Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cue Biopharma (CUE) Consolidated Net Income (2018 - 2025)

Historic Consolidated Net Income for Cue Biopharma (CUE) over the last 8 years, with Q3 2025 value amounting to -$7.4 million.

  • Cue Biopharma's Consolidated Net Income rose 1297.21% to -$7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$37.3 million, marking a year-over-year increase of 1421.73%. This contributed to the annual value of -$39.9 million for FY2024, which is 1941.88% up from last year.
  • Per Cue Biopharma's latest filing, its Consolidated Net Income stood at -$7.4 million for Q3 2025, which was up 1297.21% from -$8.4 million recorded in Q2 2025.
  • In the past 5 years, Cue Biopharma's Consolidated Net Income ranged from a high of -$7.4 million in Q3 2025 and a low of -$14.3 million during Q1 2022
  • Its 5-year average for Consolidated Net Income is -$11.2 million, with a median of -$12.1 million in 2024.
  • As far as peak fluctuations go, Cue Biopharma's Consolidated Net Income tumbled by 8042.44% in 2022, and later soared by 2772.49% in 2024.
  • Cue Biopharma's Consolidated Net Income (Quarter) stood at -$7.9 million in 2021, then plummeted by 80.42% to -$14.2 million in 2022, then rose by 9.18% to -$12.9 million in 2023, then rose by 27.72% to -$9.3 million in 2024, then grew by 21.09% to -$7.4 million in 2025.
  • Its Consolidated Net Income was -$7.4 million in Q3 2025, compared to -$8.4 million in Q2 2025 and -$12.1 million in Q1 2025.